GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Interest Coverage

Mural Oncology (Mural Oncology) Interest Coverage : N/A (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Mural Oncology's Operating Income for the three months ended in Mar. 2024 was $-34.03 Mil. Mural Oncology's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Mural Oncology PLC has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Mural Oncology's Interest Coverage or its related term are showing as below:


MURA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 156.65
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Mural Oncology Interest Coverage Historical Data

The historical data trend for Mural Oncology's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mural Oncology Interest Coverage Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23
Interest Coverage
N/A N/A N/A

Mural Oncology Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only No Debt N/A N/A N/A N/A

Competitive Comparison of Mural Oncology's Interest Coverage

For the Biotechnology subindustry, Mural Oncology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Interest Coverage falls into.



Mural Oncology Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mural Oncology's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Mural Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-196.24 Mil. And its Long-Term Debt & Capital Lease Obligation was $8.91 Mil.

GuruFocus does not calculate Mural Oncology's interest coverage with the available data.

Mural Oncology's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Mural Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-34.03 Mil. And its Long-Term Debt & Capital Lease Obligation was $7.33 Mil.

GuruFocus does not calculate Mural Oncology's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Mural Oncology  (NAS:MURA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Mural Oncology Interest Coverage Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology (Mural Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin, IRL, D02 T380
Website
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines